NCT04877834View on ClinicalTrials.gov

Bioequivalence Study of DelanzoᵀᴹDR 60mg (Dexlansoprazole) Capsule With Dexilant® 60mg (Dexlansoprazole) Capsule in Healthy Pakistani Subjects.

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

September 18, 2021

Primary Completion Date

October 25, 2022

Study Completion Date

November 25, 2022

Conditions
HealthyBioequivalence Study
Interventions
DRUG

Dexlansoprazole

Dexlansoprazole capsule prepared by SAMI Pharmaceuticals will be administered to this arm.

DRUG

Dexlansoprazole

Dexlansoprazole capsule prepared by Takeda Pharmaceutical Company will be administered to this arm.

Trial Locations (1)

75270

Center for Bioequivalence Studies and clinical research, Karachi

All Listed Sponsors
collaborator

SAMI Pharmaceutical, Karachi Pakistan

UNKNOWN

lead

University of Karachi

OTHER

NCT04877834 - Bioequivalence Study of DelanzoᵀᴹDR 60mg (Dexlansoprazole) Capsule With Dexilant® 60mg (Dexlansoprazole) Capsule in Healthy Pakistani Subjects. | Biotech Hunter | Biotech Hunter